Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel
Journal of Drugs in Dermatology · 01.05.2026 · 25 (5) · 413-420
DOI: 10.36849/jdd.9954 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Drugs in Dermatology, online erschienen am 01.04.2026. Verfasst von Brooke Bartley und 11 weiteren Autor:innen. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Cutaneous Squamous Cell Carcinoma, Immune Checkpoint Inhibitors.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Bartley, B., Rosenberg, A., DeBusk, L., Farberg, A. S., Dinehart, S. M., Trotter, S. C., Ackerman, L., Groisser, D., Schlesinger, T., Rosso, J. Q. D., Lebwohl, M., & Rigel, D. (2026). Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel. Journal of Drugs in Dermatology, 25(5), 413-420. https://doi.org/10.36849/jdd.9954
Vancouver
Bartley B, Rosenberg A, DeBusk L, Farberg AS, Dinehart SM, Trotter SC, et al. Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel. Journal of Drugs in Dermatology. 2026;25(5):413-420. doi:10.36849/jdd.9954
BibTeX
@article{Bartley2026,
author = {Bartley, Brooke and Rosenberg, Angela and DeBusk, Lauren and Farberg, Aaron S and Dinehart, Scott M and Trotter, Shannon C and Ackerman, Lindsay and Groisser, Daniel and Schlesinger, Todd and Rosso, James Q Del and Lebwohl, Mark and Rigel, Darrell},
title = {Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel},
journal = {Journal of Drugs in Dermatology},
year = {2026},
volume = {25},
number = {5},
pages = {413--420},
doi = {10.36849/jdd.9954}
}
EUVIMED